Top

Current Cardiovascular Imaging Reports

Published in:

30-08-2023 | Positron Emission Tomography

Current Role of Myocardial Viability Imaging Using Positron Emission Tomography in Patients with Chronic Ischemic Heart Failure and Left Ventricular Dysfunction

Authors: Mette Louise Gram Kjærulff, Simon Madsen, Thien Vinh Luong, Kasper Pryds, Roni Nielsen, Lars Christian Gormsen

Published in: Current Cardiovascular Imaging Reports | Issue 10/2023

Abstract

Purpose of Review

It is currently debated what role cardiac viability imaging plays in clinical practice, as newer randomized studies have refuted the previously reported beneficial effects of non-invasive imaging-guided decision-making for revascularization. This review provides an overview of previous literature and recent findings on the clinical use of viability PET imaging in revascularization decision-making for patients with chronic ischemic heart failure.

Recent Findings

Recent studies have concluded that preoperative myocardial viability assessment by PET imaging does not have significant predictive value for outcomes following revascularization in patients with ischemic heart failure. Alternative PET metrics, e.g., myocardial flow reserve obtained through a less time-consuming protocol compared to FDG PET, have the potential to predict revascularization outcomes.

Summary

Viability assessment prior to revascularization may not be as significant in clinical practice as it was previously thought. This shift in perspective is likely due to the retrospective nature of earlier studies, coupled with the progress made in heart failure treatment.

Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics – 2021 update: a report from the American Heart Association. Circulation. 2021;143(8):e254–743. https://doi.org/10.1161/CIR.0000000000000950.CrossRefPubMed

Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021;23(3):352–80. https://doi.org/10.1002/ejhf.2115.CrossRefPubMed

Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018;391(10120):572–80. https://doi.org/10.1016/S0140-6736(17)32520-5.CrossRefPubMedPubMedCentral

Almeida AG, Carpenter JP, Cameli M, Donal E, Dweck MR, Flachskampf FA, et al. Multimodality imaging of myocardial viability: an expert consensus document from the European Association of Cardiovascular Imaging (EACVI). Eur Heart J Cardiovasc Imaging. 2021;22(8):e97–e125. https://doi.org/10.1093/ehjci/jeab053.CrossRefPubMed

Di Carli MF, Maddahi J, Rokhsar S, Schelbert HR, Bianco-Batlles D, Brunken RC, Fromm B. Long-term survival of patients with coronary artery disease and left ventricular dysfunction: implications for the role of myocardial viability assessment in management decisions. J Thorac Cardiovasc Surg. 1998;116(6):997–1004. https://doi.org/10.1016/S0022-5223(98)70052-2.CrossRefPubMed

Beanlands RS, Ruddy TD, deKemp RA, et al. Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol. 2002;40(10):1735–43. https://doi.org/10.1016/s0735-1097(02)02489-0.CrossRefPubMed

Di Carli MF, Asgarzadie F, Schelbert HR, et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation. 1995;92(12):3436–44. https://doi.org/10.1161/01.cir.92.12.3436.CrossRefPubMed

Ling LF, Marwick TH, Flores DR, et al. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: inducible ischemia versus hibernating myocardium. Circ Cardiovasc Imaging. 2013;6(3):363–72. https://doi.org/10.1161/CIRCIMAGING.112.000138.CrossRefPubMed

Panza JA, Ellis AM, Al-Khalidi HR, Holly TA, Berman DS, Oh JK, et al. Myocardial viability and long-term outcomes in ischemic cardiomyopathy. N Engl J Med. 2019;381:739–48. https://doi.org/10.1056/NEJMoa1807365.CrossRefPubMedPubMedCentral

10.

Perera D, Clayton T, O’Kane PD, Greenwood JP, Weerackody R, REVIVED-BCIS2 Investigators, et al. Percutaneous revascularization for ischemic left ventricular dysfunction. N Engl J Med. 2022;387(15):1351–60. https://doi.org/10.1056/NEJMoa2206606.CrossRefPubMed

11.

Babes EE, Tit DM, Bungau AF, Bustea C, Rus M, Bungau SG, et al. Myocardial viability testing in the management of ischemic heart failure. Life (Basel). 2022;12(11):1760. https://doi.org/10.3390/life12111760.CrossRefPubMedPubMedCentral

12.

Beanlands RS, Hendry PJ, Masters RG, deKemp RA, Woodend K, Ruddy TD. Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imaging. Circulation. 1998;98(19 Suppl):II51–6.PubMed

13.

Maddahi J, Schelbert H, Brunken R, Di Carli M. Role of thallium-201 and PET imaging in evaluation of myocardial viability and management of patients with coronary artery disease and left ventricular dysfunction. J Nuclear Med. 1994;35(4):707–15.

14.

Schinkel AFL, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol. 2007;32(7):375–410. https://doi.org/10.1016/j.cpcardiol.2007.04.001.CrossRefPubMed

15.

Bax JJ, Poldermans D, Elhendy A, Boersma E, Rahimtoola SH. Sensitivity, specificity, and predictive accuracies of various noninvasive techniques for detecting hibernating myocardium. Curr Probl Cardiol. 2001;26(2):147–86. https://doi.org/10.1067/mcd.2001.109973.CrossRefPubMed

16.

Murthy VL, Naya M, Foster CR, Hainer J, Gaber M, Di Carli G, et al. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation. 2011;124(20):2215–24. https://doi.org/10.1161/CIRCULATIONAHA.111.050427.CrossRefPubMedPubMedCentral

17.

Bateman TM, Heller GV, McGhie AI, Friedman JD, Case JA, Bryngelson JR, et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT. J Nucl Cardiol. 2006;13(1):24–33. https://doi.org/10.1016/j.nuclcard.2005.12.004.CrossRefPubMed

18.

Kloner RA. Stunned and hibernating myocardium: where are we nearly 4 decades later? J Am Hear Assoc. 2020;9(3):e015502. https://doi.org/10.1161/JAHA.119.015502.CrossRef

19.

Madsen S, Dias AH, Lauritsen KM, Bouchelouche K, Tolbod LP, Gormsen LC. Myocardial viability testing by positron emission tomography: basic concepts, mini-review of the literature and experience from a tertiary PET center. Semin Nucl Med. 2020;50(3):248–59. https://doi.org/10.1053/j.semnuclmed.2020.02.010.CrossRefPubMed

20.

Chen K, Miller EJ, Sadeghi MM. PET based imaging of ischemic heart disease. PET Clin. 2019;14(2):211–21. https://doi.org/10.1016/j.cpet.2018.12.003.CrossRefPubMedPubMedCentral

21.

Grönman M, Tarkia M, Stark C, Vähäsilta T, Kibiniemi T, Lubberink M, et al. Assessment of myocardial viability with [¹⁵O]water PET: a validation study in experimental myocardial infarction. J Nucl Cardiol. 2021;28(4):1271–80. https://doi.org/10.1007/s12350-019-01818-5.CrossRefPubMed

22.

Cleland JGF, Calvert M, Freemantle N, Arrow Y, Ball SG, Bonser RS, et al. The heart failure revascularisation trial (HEART). Eur J Heart Fail. 2011;13(2):227–33. https://doi.org/10.1093/eurjhf/hfq230.CrossRefPubMed

23.

Wolff G, Dimitroulis D, Andreotti F, Kołodziejczak M, Jung C, Scicchitano P, et al. Survival benefits of invasive versus conservative strategies in heart failure in patients with reduced ejection fraction and coronary artery disease: a meta-analysis. Circ Heart Fail. 2017;10(1):e003255. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003255.CrossRefPubMed

24.

Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med. 2016;374(16):1511–20. https://doi.org/10.1056/NEJMoa1602001.CrossRefPubMedPubMedCentral

25.

Saltiel J, Lespérance J, Bourassa MG, Castonguay Y, Campeau L, Grondin P. Reversibily of left ventricular dysfunction following aorto-coronary by-pass grafts. Am J Roentgenol Radium Ther Nucl Med. 1970;110(4):739–46. https://doi.org/10.2214/ajr.110.4.739.CrossRefPubMed

26.

Horn HR, Teichholz LE, Cohn PF, Herman MV, Gorlin R. Augmentation of left ventricular contraction pattern in coronary artery disease by an inotropic catecholamine. The epinephrine ventriculogram. Circulation. 1974;49(6):1063–71. https://doi.org/10.1161/01.cir.49.6.1063.CrossRefPubMed

27.

Rahimtoola SH. The hibernating myocardium. Am Heart J. 1989;117(1):211–21. https://doi.org/10.1016/0002-8703(89)90685-6.CrossRefPubMed

28.

Rahimtoola SH. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation. 1985;72(6 Pt 2):V123–235.PubMed

29.

Uebleis C, Hellweger S, Laubender RP, et al. The amount of dysfunctional but viable myocardium predicts long-term survival in patients with ischemic cardiomyopathy and left ventricular dysfunction. Int J Cardiovasc Imaging. 2013;29(7):1645–53. https://doi.org/10.1007/s10554-013-0254-2.CrossRefPubMed

30.

Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39(7):1151–8. https://doi.org/10.1016/s0735-1097(02)01726-6.CrossRefPubMed

31.

Orlandini A, Castellana N, Pascual A, Botto F, Bahot MC, Chacon C, Diaz ML, Diaz R. Myocardial viability for decision-making concerning revascularization in patients with left ventricular dysfunction and coronary artery disease: a meta-analysis of non-randomized and randomized studies. Int J Cardiol. 2015;182:494–9. https://doi.org/10.1016/j.ijcard.2015.01.025.CrossRefPubMed

32.

Inaba Y, Chen JA, Bergmann SR. Quantity of viable myocardium required to improve survival with revascularization in patients with ischemic cardiomyopathy: a meta-analysis. J Nucl Cardiol. 2010;17(4):646–54. https://doi.org/10.1007/s12350-010-9226-2.CrossRefPubMed

33.

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42(36):3599–726. https://doi.org/10.1093/eurheartj/ehab368.CrossRefPubMed

34.

Liu Y, Jiang Y, Yang X, Geng B, Liu Y, Shang X, et al. Limited prognostic value of myocardial viability assessment in patients with coronary artery diseases and severe left ventricular dysfunction. J Thorax Dis. 2018;10(4):2249–55. https://doi.org/10.21037/jtd.2018.04.03.CrossRef

35.

Beanlands RS, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized controlled trial (PARR-2). JACC. 2007;50(20):2002–12. https://doi.org/10.1016/j.jacc.2007.09.006.CrossRefPubMed

36.

McArdle B, Shukla T, Nichol G, et al. Long-term follow-up of outcomes with F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction secondary to coronary disease. Circ Cardiovasc Imaging. 2016;9(9):e004331. https://doi.org/10.1161/CIRCIMAGING.115.004331.CrossRef

37.

Siebelink HM, Blanksma PK, Crijns HJ, Bax JJ, van Boven AJ, Kingma T, et al. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. J Am Coll Cardiol. 2001;37(1):81–8. https://doi.org/10.1016/s0735-1097(00)01087-1.CrossRefPubMed

38.

Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011;364(17):1617–25. https://doi.org/10.1056/NEJMoa1100358.CrossRefPubMedPubMedCentral

39.

Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl Med J. 2011;364(17):1607–16. https://doi.org/10.1056/NEJMoa1100356.CrossRef

40.

Petrie MC, Jhund PS, She L, Adlbrecht C, Doenst T, Panza JA, et al. Ten year outcomes after coronary artery bypass grafting according to age in patients with heart failure and left ventricular systolic dysfunction: an analysis of the extended follow-up of the STICH trial (Surgical Treatment for Ischemic Heart Failure). Circulation. 2016;134(18):1314–24. https://doi.org/10.1161/CIRCULATIONAHA.116.024800.CrossRefPubMedPubMedCentral

41.

D’Egidio G, Nichol G, Williams KA, et al. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial. JACC Cardiovasc Imaging. 2009;2(9):1060–8. https://doi.org/10.1016/j.jcmg.2009.02.017.CrossRefPubMed

42.

Abraham A, Nichol G, Williams KA, Guo A, deKemp RA, Garrard L, et al. 18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: the Ottawa-FIVE substudy of the PARR 2 trial. J Nucl Med. 2010;51(4):567–74. https://doi.org/10.2967/jnumed.109.065938.CrossRefPubMed

43.

Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165. https://doi.org/10.1093/eurheartj/ehy394.CrossRefPubMed

44.

Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Card Fail. 2022;28(5):e1–e167. https://doi.org/10.1016/j.cardfail.2022.02.010.CrossRef

45.

Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e18–e114. https://doi.org/10.1161/CIR.0000000000001038.CrossRefPubMed

46.

••Davoudi F, Miyashita S, Yoo TK, Imahira U, Kimmelstiel C, Huggins GS, et al. Do patients with non-viable myocardium from ischemic cardiomyopathy benefit from revascularization? A systematic review and meta-analysis. Cardiovasc Revasc Med. 2023 Feb;47:27–1. https://doi.org/10.1016/j.carrev.2022.08.032. This meta-analysis including 12 studies analyzed revascularization benefits for non-viable myocardium in 1363 patients with chronic ischemic heart failure and left ventricular ejection fraction <50%, and found no significant role of preoperative viability status in predicting prognosis after revascularization.CrossRefPubMed

47.

••Luong TV, Ebbehoj A, MLG K, Nielsen R, Nielsen PH, Christiansen EH, et al. Clinical use of cardiac 18 F-FDG viability PET: a retrospective study of 44 patients undergoing post-test revascularization. Int J Cardiovasc Imaging. 2022;38(11):2447–58. https://doi.org/10.1007/s10554-022-02661-5. This study provides significant insights into the assessment of whether myocardial glucose uptake and other viability PET parameters can serve as predictive factors for improvements in left ventricular ejection fraction and patient survival following revascularization, which the study disproves.CrossRefPubMed

48.

Benz DC, Kaufmann PA, von Felten E, Benetos G, Rampidis G, Messerli M, et al. Prognostic value of quantitative metrics from positron emission tomography in ischemic heart failure. JACC Cardiovasc Imaging. 2021;14(2):454–64. https://doi.org/10.1016/j.jcmg.2020.05.033.CrossRefPubMed

49.

Wang J, Li JM, Li S, Hsu B. Absolute resting ¹³N-ammonia PET myocardial blood flow for predicting myocardial viability and recovery of ventricular function after coronary artery bypass grafting. J Nucl Cardiol. 2022;29(3):987–99. https://doi.org/10.1007/s12350-020-02388-7.CrossRefPubMed

50.

Stankewicz MA, Mansour CS, Eisner RL, Churchwell KB, Williams BR, Sigman SR, et al. Myocardial viability assessment by PET: (82)Rb defect washout does not predict the results of metabolic-perfusion mismatch. J Nucl Med. 2005;46(10):1602–9.PubMed

51.

Moody JB, Hiller KM, Lee BC, Poitrasson-Rivière A, Corbett JR, Weinberg RL, et al. The utility of ⁸²Rb PET for myocardial viability assessment: comparison with perfusion-metabolism ⁸²Rb-¹⁸F-FDG PET. J Nucl Cardiol. 2019;26(2):374–86. https://doi.org/10.1007/s12350-019-01615-0.CrossRefPubMed

52.

O’Meara E, Mielniczuk LM, Wells GA, deKemp RA, Klein R, Coyle D, IMAGE HF investigators, et al. Alternative imaging modalities in ischemic heart failure (AIMI-HF) IMAGE HF Project I-A: study protocol for a randomized controlled trial. Trials. 2013;16(14):218. https://doi.org/10.1186/1745-6215-14-218.CrossRef

53.

Conti M, Eriksson L. Physics of pure and non-pure positron emitters for PET: a review and a discussion. EJNMMI Phys. 2016;3(1):8. https://doi.org/10.1186/s40658-016-0144-5.CrossRefPubMedPubMedCentral

54.

Harms HJ, Knaapen P, de Haan S, Halbmeijer R, Lammertsma AA, Lubberink M. Automatic generation of absolute myocardial blood flow images using [15O]H2O and a clinical PET/CT scanner. Eur J Nucl Med Mol Imaging. 2011;38(5):930–9. https://doi.org/10.1007/s00259-011-1730-3.CrossRefPubMedPubMedCentral

55.

Curtis JP, Sokol SI, Wang Y, Rathore SS, Radford MJ, Krumholz HM. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol. 2003;42(4):736–42. https://doi.org/10.1016/s0735-1097(03)00789-7.CrossRefPubMed

56.

••Ryan M, Morgan H, Chiribiri A, Nagel E, Cleland J, Perera D. Myocardial viability testing: all STICHed up, or about to be REVIVED? Eur Heart J. 2022;43(2):118–26. https://doi.org/10.1093/eurheartj/ehab729. This paper presents significant inquiries regarding the validity of left ventricular ejection fraction as a surrogate endpoint for clinical outcomes in patients who have undergone revascularization, thus contributing to an important debate.CrossRefPubMed

57.

Samady H, Elefteriades JA, Abbott BG, Mattera JA, McPherson CA, Wackers FJ. Failure to improve left ventricular function after coronary revascularization for ischemic cardiomyopathy is not associated with worse outcome. Circulation. 1999;100(12):1298–304. https://doi.org/10.1161/01.cir.100.12.1298.CrossRefPubMed

Title: Current Role of Myocardial Viability Imaging Using Positron Emission Tomography in Patients with Chronic Ischemic Heart Failure and Left Ventricular Dysfunction
Authors: Mette Louise Gram Kjærulff
Simon Madsen
Thien Vinh Luong
Kasper Pryds
Roni Nielsen
Lars Christian Gormsen
Publication date: 30-08-2023
Publisher: Springer US
Keywords: Positron Emission Tomography
Heart Failure
CABG
CABG
Published in: Current Cardiovascular Imaging Reports / Issue 10/2023
Print ISSN: 1941-9066
Electronic ISSN: 1941-9074
DOI: https://doi.org/10.1007/s12410-023-09582-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Current Role of Myocardial Viability Imaging Using Positron Emission Tomography in Patients with Chronic Ischemic Heart Failure and Left Ventricular Dysfunction

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content